Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis
| Autor: | Kye Hun Kim, Hyung Wook Park, Sun Ho Hwang, Sang Yup Lim, Young Joon Hong, Jeong Gwan Cho, Weon Kim, Jong Chun Park, Young Keun Ahn, Sang Rok Lee, Myung Ho Jeong, Seo Na Hong, Ju Han Kim, Nam Sik Yun, Jung Chaee Kang |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Bare-metal stent
Male medicine.medical_specialty Time Factors medicine.medical_treatment Abciximab Lumen (anatomy) Coronary Angiography Coronary Restenosis Blood Vessel Prosthesis Implantation Immunoglobulin Fab Fragments Restenosis Coated Materials Biocompatible Predictive Value of Tests Intravascular ultrasound Medicine Humans cardiovascular diseases Postoperative Period Prospective Studies Ultrasonography Interventional Neointimal hyperplasia medicine.diagnostic_test business.industry Coronary Stenosis Stent Antibodies Monoclonal Middle Aged equipment and supplies medicine.disease Predictive value of tests Female Stents Radiology Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug Follow-Up Studies |
| Zdroj: | International journal of cardiology. 123(1) |
| ISSN: | 1874-1754 |
| Popis: | Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates.This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n=69) compared to bare metal stent (BMS) implantation (n=69). All patients underwent IVUS follow-up at 6 months.At follow-up coronary angiogram, the restenosis rate and late loss were 12%, 0.30+/-0.24 mm in abciximab-coated stent group and 29%, 0.68+/-0.36 mm in BMS group (p=0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9+/-1.6 mm(2) vs. 4.5+/-1.7 mm(2), p=0.001, and 1.9+/-1.5 mm(2) vs. 3.3+/-1.9 mm(2), p0.001, respectively). Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA6.0 mm(2), from 6 to 7.5 mm(2), and7.5 mm(2), respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n=3 (4%) vs. BMS: n=4 (6%), p=0.698].Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect